IL102198A - A pharmaceutical preparation containing gastrol acetate - Google Patents
A pharmaceutical preparation containing gastrol acetateInfo
- Publication number
- IL102198A IL102198A IL10219892A IL10219892A IL102198A IL 102198 A IL102198 A IL 102198A IL 10219892 A IL10219892 A IL 10219892A IL 10219892 A IL10219892 A IL 10219892A IL 102198 A IL102198 A IL 102198A
- Authority
- IL
- Israel
- Prior art keywords
- megestrol acetate
- concentration
- formulation
- polysorbate
- weight
- Prior art date
Links
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 title claims abstract description 55
- 229960004296 megestrol acetate Drugs 0.000 title claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 title description 7
- 239000000725 suspension Substances 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 238000009472 formulation Methods 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 10
- 239000000796 flavoring agent Substances 0.000 claims abstract description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 10
- 229920000136 polysorbate Polymers 0.000 claims abstract description 8
- 229950008882 polysorbate Drugs 0.000 claims abstract description 8
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 7
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 5
- 239000003765 sweetening agent Substances 0.000 claims abstract description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 15
- 229920000053 polysorbate 80 Polymers 0.000 claims description 15
- 229940068968 polysorbate 80 Drugs 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 13
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 6
- 239000004299 sodium benzoate Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 235000019223 lemon-lime Nutrition 0.000 claims description 5
- 229940100474 polyethylene glycol 1450 Drugs 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000001509 sodium citrate Substances 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 4
- 230000003139 buffering effect Effects 0.000 claims description 2
- 239000000872 buffer Substances 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 238000004062 sedimentation Methods 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 5
- 229940100692 oral suspension Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 238000005189 flocculation Methods 0.000 description 3
- 230000016615 flocculation Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001935 peptisation Methods 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- BKWJSCFKITXBBM-NTNOATJHSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-10,13-dimethyl-6-methylidene-2,7,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical class C1C(=C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 BKWJSCFKITXBBM-NTNOATJHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229940063223 depo-provera Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71715591A | 1991-06-18 | 1991-06-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL102198A0 IL102198A0 (en) | 1993-01-14 |
| IL102198A true IL102198A (en) | 1996-07-23 |
Family
ID=24880926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10219892A IL102198A (en) | 1991-06-18 | 1992-06-15 | A pharmaceutical preparation containing gastrol acetate |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5338732A (cs) |
| EP (1) | EP0519351B1 (cs) |
| JP (1) | JP3450356B2 (cs) |
| KR (1) | KR100211192B1 (cs) |
| CN (1) | CN1038904C (cs) |
| AT (1) | ATE142882T1 (cs) |
| AU (1) | AU647933B2 (cs) |
| CA (1) | CA2071141A1 (cs) |
| CZ (1) | CZ289620B6 (cs) |
| DE (1) | DE69213836T2 (cs) |
| DK (1) | DK0519351T3 (cs) |
| ES (1) | ES2091977T3 (cs) |
| FI (1) | FI101602B1 (cs) |
| GR (1) | GR3021072T3 (cs) |
| HK (1) | HK1005017A1 (cs) |
| HU (1) | HU213511B (cs) |
| IE (1) | IE77167B1 (cs) |
| IL (1) | IL102198A (cs) |
| MX (1) | MX9202944A (cs) |
| SK (1) | SK281841B6 (cs) |
| TW (1) | TW211520B (cs) |
| ZA (1) | ZA924282B (cs) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698562A (en) * | 1991-10-08 | 1997-12-16 | Ascent Pediatrics, Inc. | Palatable trimethoprim oral solution |
| US5563177A (en) * | 1995-01-30 | 1996-10-08 | American Home Products Corporation | Taste masking guaifenesin containing liquids |
| US6268356B1 (en) | 1998-04-20 | 2001-07-31 | Pharmaceutical Resources, Inc. | Flocculated suspension of megestrol acetate |
| US6028065A (en) * | 1998-04-20 | 2000-02-22 | Pharmaceutical Resources, Inc. | Flocculated suspension of megestrol acetate |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| US20030198679A1 (en) * | 2000-11-08 | 2003-10-23 | Kundu Subhas C. | Flocculated pharmaceutical suspensions and methods for actives |
| EP1275377B1 (en) * | 2001-07-11 | 2003-06-18 | Apr Applied Pharma Research S.A. | Granulates containing liposoluble substances and process of preparation thereof |
| US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
| JP4865990B2 (ja) * | 2002-04-12 | 2012-02-01 | エラン ファーマ インターナショナル，リミティド | ナノ粒子メゲストロール製剤 |
| US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
| US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
| DE10224086A1 (de) * | 2002-05-31 | 2003-12-11 | Bayer Ag | Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker |
| KR100841082B1 (ko) | 2006-08-23 | 2008-06-24 | 대원제약주식회사 | 메게스트롤 아세테이트의 서상화된 현탁제 |
| KR20080035374A (ko) * | 2006-10-19 | 2008-04-23 | 주식회사 엘지생명과학 | 약제학적으로 안정한 메게스트롤 물질의 현탁액제 |
| CN101678112B (zh) * | 2007-01-19 | 2016-08-31 | 哈南亚有限公司 | 用于递送治疗剂的方法和组合物 |
| US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| US20100137424A1 (en) * | 2007-01-22 | 2010-06-03 | Mostafa Akbarieh | Pharmaceutical compositions comprising nebivolol or a nebivolol analogue |
| TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| WO2010101989A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| KR101279568B1 (ko) * | 2010-12-10 | 2013-07-15 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | 메게스트롤 아세테이트를 포함하는 경구용 약학 조성물 |
| CN113274351B (zh) * | 2020-02-20 | 2024-04-12 | 东曜药业有限公司 | 一种口服醋酸甲地孕酮混悬液及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB870286A (en) * | 1958-11-04 | 1961-06-14 | British Drug Houses Ltd | Improvements in or relating to 6-methyl-3-oxo-í~-steroid compounds |
| FR2290906A1 (fr) * | 1974-11-13 | 1976-06-11 | Dick Pierre | Nouvelles associations hormonales synergisees pour l'implantation d'animaux de boucherie |
| US4370321A (en) * | 1976-09-01 | 1983-01-25 | Mead Johnson And Company | Progestational adjuvant therapy |
| JPS5522631A (en) * | 1978-08-07 | 1980-02-18 | Ota Seiyaku Kk | Readily absorbable nifedipine preparation |
| US4402695A (en) * | 1980-01-21 | 1983-09-06 | Alza Corporation | Device for delivering agent in vagina |
| US4396615A (en) * | 1981-06-24 | 1983-08-02 | Duke University | Method of treating androgen-related disorders |
| US4666885A (en) * | 1985-02-08 | 1987-05-19 | Fernand Labrie | Combination therapy for treatment of female breast cancer |
| US4760053A (en) * | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| US4782047A (en) * | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
-
1992
- 1992-05-13 US US07/882,218 patent/US5338732A/en not_active Expired - Lifetime
- 1992-06-11 ZA ZA924282A patent/ZA924282B/xx unknown
- 1992-06-12 DE DE69213836T patent/DE69213836T2/de not_active Expired - Fee Related
- 1992-06-12 CA CA002071141A patent/CA2071141A1/en not_active Abandoned
- 1992-06-12 EP EP92109946A patent/EP0519351B1/en not_active Expired - Lifetime
- 1992-06-12 ES ES92109946T patent/ES2091977T3/es not_active Expired - Lifetime
- 1992-06-12 TW TW081104618A patent/TW211520B/zh not_active IP Right Cessation
- 1992-06-12 DK DK92109946.1T patent/DK0519351T3/da active
- 1992-06-12 AT AT92109946T patent/ATE142882T1/de not_active IP Right Cessation
- 1992-06-15 IL IL10219892A patent/IL102198A/en not_active IP Right Cessation
- 1992-06-15 KR KR1019920010328A patent/KR100211192B1/ko not_active IP Right Cessation
- 1992-06-15 FI FI922764A patent/FI101602B1/fi active
- 1992-06-16 CZ CS19921853A patent/CZ289620B6/cs not_active IP Right Cessation
- 1992-06-16 SK SK1853-92A patent/SK281841B6/sk not_active IP Right Cessation
- 1992-06-17 MX MX9202944A patent/MX9202944A/es unknown
- 1992-06-17 HU HU9202029A patent/HU213511B/hu unknown
- 1992-06-17 JP JP19889292A patent/JP3450356B2/ja not_active Expired - Lifetime
- 1992-06-17 CN CN92104762A patent/CN1038904C/zh not_active Expired - Fee Related
- 1992-06-17 AU AU18281/92A patent/AU647933B2/en not_active Expired
- 1992-07-01 IE IE921958A patent/IE77167B1/en not_active IP Right Cessation
-
1996
- 1996-09-19 GR GR960400478T patent/GR3021072T3/el unknown
-
1998
- 1998-05-15 HK HK98104209A patent/HK1005017A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5338732A (en) | Megestrol acetate formulation | |
| US7300670B2 (en) | Oral suspension formulation | |
| US6656505B2 (en) | Method for forming an aqueous flocculated suspension | |
| JP2847134B2 (ja) | 経口投与用イブプロフェン組成物 | |
| JP6092629B2 (ja) | リファキシミン使用準備済懸濁液 | |
| JPH0363219A (ja) | 本質的に水に不溶な薬剤活性体のための薬剤水懸濁液 | |
| WO2007019184A2 (en) | Oral suspension of prednisolone acetate | |
| WO1997016196A1 (en) | Improved process and composition for therapeutic cisplatin (cddp) | |
| US6593320B2 (en) | Flocculated suspension of megestrol acetate | |
| US20020028794A1 (en) | Megestrol acetate suspension | |
| WO2001026626A1 (en) | Flocculated suspension of megestrol acetate | |
| US20180311160A1 (en) | Physically and chemically stable oral suspensions of givinostat | |
| EP0468232A2 (en) | Suspending syrups | |
| KR100841082B1 (ko) | 메게스트롤 아세테이트의 서상화된 현탁제 | |
| US20040198634A1 (en) | Flocculated pharmaceutical suspensions and methods for actives | |
| KR20110042874A (ko) | 메게스트롤 아세테이트를 포함하는 현탁제 | |
| JP2001072576A (ja) | 経口用医薬品組成物 | |
| HU211660A9 (hu) | Megestrol-acetátot tartalmazó gyógyszerkészítmények | |
| EP4382093A1 (en) | Oral suspensions comprising capecitabine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |